The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.
Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MSc
April 22nd 2023The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]
Open-Label Analysis Highlights Long-Term Safety of BTK Inhibitor Tolebrutinib
April 22nd 2023There were no observed tolebrutinib dose effect for treatment-emergent adverse events in the double-blind portion, as well as no new safety signals seen for those who crossed over in the open-label extension.
Targeting Blood Vessels to Improve Treatment for Alzheimer Disease: Costantino Iadecola, MD
April 22nd 2023The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]
Advances in Neurology, Contributions to Brain Health: Costantino Iadecola, MD
April 20th 2023The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about brain health in relation to vascular health ahead of the 2023 AAN annual meeting. [WATCH TIME: 3 minutes]
Analyzing Specific Pathways in Cells to Prevent Relapse in NMOSD: Shuhei Nishiyama, MD, PhD
April 19th 2023The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about his research of cell function in NMOSD to be presented at the upcoming AAN annual meeting. [WATCH TIME: 6 minutes]
Specific Considerations for Monoclonal Antibody Treatment in NMOSD: Shuhei Nishiyama, MD, PhD
April 17th 2023The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about having safer and more specific treatments for NMOSD that are antigen-specific. [WATCH TIME: 4 minutes]
Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS
May 19th 2022The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc
May 19th 2022The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease
May 18th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.
Validating Tears as a Biomarker in Atypical Presentations of Parkinson Disease: Mark Lew, MD
May 11th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the efforts needed to validate tears as a biomarker in patients who don’t present with typical Parkinson disease. [WATCH TIME: 4 minutes]
The Future of Tears as a Biomarker for Neurodegenerative Disorders: Mark Lew, MD
May 9th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps in how we can expand on tears as a valuable biomarker for neurodegenerative diseases. [WATCH TIME: 4 minutes]
Regenerative Medicine for Neurologic Injury and the Potential of SB623
April 29th 2022Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.
AAN Annual Meeting 2022: Top Expert Interviews
April 28th 2022Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.
Patient Survey Suggests Preference for Once-Nightly Dosing With FT218 in Narcolepsy
April 27th 2022Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.
NeuroVoices: Mark Lew, MD, on Exploring Reflex Tears as a Biomarker for Parkinson Disease
April 27th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.
Addition of Mechanical Thrombectomy Improves Odds of Good Outcome in Elderly Poststroke Patients
April 26th 2022Following respective improvements in odds of good and poor outcomes, investigators concluded that the addition of mechanical thrombectomy should be considered over best medical management practices alone.
Aligning Patient, Clinician, and Caregiver Goals in Alzheimer Disease: Sharon Cohen, MD, FRCPC
April 26th 2022The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]